ライフサイエンスコーパス: antibacterial

1 dicinal behaviours and dosing of this living antibacterial.

2 s to both activation and deactivation of the antibacterial.

3 abaceae are promising lead compounds for new antibacterials.

4 nd has the potential to aid discovery of new antibacterials.

5 is not exploited by any clinically approved antibacterials.

6 and identified from Cystobacter sp as novel antibacterials.

7 d be a target for the future design of novel antibacterials.

8 low spent S. cerevisiae growth media to have antibacterial action against Streptococcus bacteria.

9 that Al toxicity plays a central role in the antibacterial action of a kaolin-rich clay from the Colo

10 thelicidins, which in turn, are critical for antibacterial action.

11 DNA gyrase and topoisomerase IV, displaying antibacterial activities against Gram-positive and Gram-

12 6-substituted analogues, demonstrate potent antibacterial activities against MRSA, MRSE and VRE (MIC

13 ffiliated bacterial flora had a wide-ranging antibacterial activities and potential natural product d

14 to their neuromodulatory functions, display antibacterial activities of unclear significance.

15 d exhibits antiviral, antiproliferative, and antibacterial activities typical of type I IFNs, albeit

16 nate HPs 24 and 25 were found to have potent antibacterial activities with significantly improved wat

17 The two fully processed PTM analogues showed antibacterial activities, albeit lower than that of PTM,

18 theranostic nanodrugs that display enhanced antibacterial activities, as well as aggregation-induced

19 In addition, these nanodrugs showed enhanced antibacterial activities, lowering the minimum inhibitor

20 porated into various biomaterials possessing antibacterial activities.

21 rtunity to develop derivatives with improved antibacterial activities.

22 ssess among other properties antioxidant and antibacterial activities.

23 important structural features necessary for antibacterial activity (a nitrogenous and a lipophilic c

24 Evaluation of antibacterial activity against a panel of Gram-positive

25 e reported previously as a new scaffold with antibacterial activity against an array of multidrug-res

26 bacterial RNA polymerase (RNAP) and exhibits antibacterial activity against drug-resistant bacterial

27 lin-binding proteins, resulting in intrinsic antibacterial activity against Enterobacteriaceae and re

28 Compound 1 also showed broad spectrum antibacterial activity against Escherichia coli, Mycobac

29 Bacaucin shows broad antibacterial activity against Gram-positive bacteria, b

30 l-sn-glycero-3-phosphocholine exhibited good antibacterial activity against Klebsiella planticola wit

31 isoflavonoids and stilbenoids showed potent antibacterial activity against Listeria monocytogenes an

32 Pools showed high antibacterial activity against Listeria monocytogenes: c

33 films while 11 and 12 demonstrated excellent antibacterial activity against M. tuberculosis (MIC = 3.

34 Antibacterial activity against model Gram negative and G

35 ng power and lipid peroxidation inhibition), antibacterial activity against MRSA and MSSA and cytotox

36 red ring-opened heptapeptide, shows specific antibacterial activity against MRSA by a membrane-disrup

37 signed, synthesized, and evaluated for their antibacterial activity against multidrug resistant (MDR)

38 ant activity was evaluated by DPPH assay and antibacterial activity against Pseudomonas aeruginosa an

39 One compound demonstrated the best antibacterial activity against Pseudomonas aeruginosa bo

40 tly inhibited gram negative bacteria and the antibacterial activity also increased significantly agai

41 modified PRO membranes possess much enhanced antibacterial activity and antibiofouling propensity.

42 l, cationic AMPs, which offer broad-spectrum antibacterial activity and better therapeutic potential

43 e demonstrate that bile salts increase SPI-6 antibacterial activity and that S Typhimurium kills comm

44 s with vertical orientation exhibit enhanced antibacterial activity compared with random and horizont

45 e I inhibition, binding to B-DNA duplex, and antibacterial activity has been evaluated.

46 In serum, however, C10OOc12O induced antibacterial activity in a manner suppressible by antic

47 the first time, full in situ photocontrol of antibacterial activity in the presence of bacteria was a

48 Mesenchymal stem cells (MSC) exert antibacterial activity in vitro and in acute bacterial i

49 ded by structure-based design and focused on antibacterial activity in vitro and in vivo, culminating

50 Its antibacterial activity is limited to gram positive bacte

51 resulted in a pronounced improvement in the antibacterial activity observed against Listeria monocyt

52 pectrum for V. odorata cyclotides, including antibacterial activity of cycloviolacin O2 against A. ba

53 Here, the antibacterial activity of dextran-coated nanoceria was e

54 on and physicochemical characterization, the antibacterial activity of EDP on food spoilage and food

55 nt at 45 and 55 degrees C did not affect the antibacterial activity of honey samples.

56 ing capacity, enhanced shelf life and strong antibacterial activity of linalool.

57 The goal of this report is to evaluate the antibacterial activity of monoclonal antibodies (MAbs) t

58 The demonstrated antibacterial activity of MXene coated membranes against

59 o determine the effects of MW heating on the antibacterial activity of raw rapeseed honeys against Ps

60 Here we present the antibacterial activity of self-assembled diphenylalanine

61 ization is performed to explain the enhanced antibacterial activity of the film with vertically align

62 cell membrane, suggesting that the enhanced antibacterial activity of the film with vertically align

63 Antibacterial activity of the pools and membrane permeab

64 w that mites: 1) cause beetles to reduce the antibacterial activity of their exudates but 2) there ar

65 ions eventually confirmed the broad-spectrum antibacterial activity of this new family of molecules.

66 Here, we investigate the spectrum of antibacterial activity of three phenylthiazole-substitut

67 Similarly, antibacterial activity of zein-THY/gamma-CD-IC-NF (2:1)

68 Antibacterial activity studies integrated with the outco

69 phylum Cnidaria) secrete neuropeptides with antibacterial activity that may shape the microbiome on

70 ntact AS-48 resists digestion guarantees its antibacterial activity throughout the gastrointestinal t

71 It imparted antibacterial activity to the membranes; the number of l

72 leic acid and lipid peroxidation assays; the antibacterial activity was evaluated by the hole plate a

73 However, their promising antibacterial activity was hampered in large part by the

74 Although antibacterial activity was partially compromised, a sing

75 PUM exhibits additive antibacterial activity when co-administered with Rif, ex

76 W thermal heating completely abolished honey antibacterial activity whereas conventional thermal trea

77 binations is sulbactam-ETX2514, whose potent antibacterial activity, in vivo efficacy against MDR A.

78 12-epi-pleuromutilins with extended-spectrum antibacterial activity, including activity against Gram-

79 rmone hepcidin, which, in addition to having antibacterial activity, regulates the functions of FPN.

80 in the phenolic skeleton also influenced the antibacterial activity.

81 farnesol, which is commonly known to exhibit antibacterial activity.

82 omplex lanthipeptide that has broad spectrum antibacterial activity.

83 t the effects of MW thermal heating on honey antibacterial activity.

84 mpounds significantly contribute towards its antibacterial activity.

85 fluids did not affect short-term release or antibacterial activity.

86 ver the molecular process that underlies its antibacterial activity.

87 to hydroxylamine intermediate for exhibiting antibacterial activity.

88 renylated phenolics found in pools with high antibacterial activity.

89 and gentle adhesive displacement (N-G), non-antibacterial adhesive and augmented-pressure adhesive d

90 sive and gentle adhesive displacement (A-G), antibacterial adhesive and augmented-pressure adhesive d

91 d dentin disks in 4 experimental groups: non-antibacterial adhesive and gentle adhesive displacement

92 mented-pressure adhesive displacement (N-H), antibacterial adhesive and gentle adhesive displacement

93 such as the natural product nitrofungin, the antibacterial agent chloroxylenol, and the herbicide chl

94 y of gepotidacin, a new triazaacenaphthylene antibacterial agent for the treatment of conventional an

95 and 3 warrant further investigation as novel antibacterial agents against drug-resistant enterococci.

96 Antibacterial agents have been historically studied in n

97 ns, and resistance to virtually all approved antibacterial agents is emerging in this pathogen.

98 From a public health perspective, new antibacterial agents should be evaluated and approved fo

99 er, and yet equipotent, or even more potent, antibacterial agents than the natural product, thereby s

100 or testing the susceptibility of bacteria to antibacterial agents that affect their cell wall.

101 this end, present feasible trial designs for antibacterial agents that could enable conduct of narrow

102 rsists for new, feasible pathways to develop antibacterial agents to treat people infected with drug-

103 otoswitchable antibiotics, we introduce here antibacterial agents whose activity can be controlled by

104 arget for reversal of resistance to selected antibacterial agents, and recently we described indole-b

105 s largely based on retrospective analyses of antibacterial agents, which suggest that polarity and mo

106 y is one of the most important properties of antibacterial agents.

107 biotic overuse compel us to seek alternative antibacterial agents.

108 ultimately approval of critically needed new antibacterial agents.

109 ides a paradigm shift towards development of antibacterial agents.

110 rganisms in order to preserve the utility of antibacterial agents.

111 received considerable interest as potential antibacterial agents.

112 tics as well as a lack of development of new antibacterial agents.

113 discovery and development efforts toward new antibacterial agents.

114 f flavonoids previously demonstrated to have antibacterial and anti-inflammatory effects.

115 Xyridin A, an important natural product with antibacterial and antifungal activity.

116 bited high antioxidant activity and moderate antibacterial and antimutagenic action.

117 he objective of this study was to screen the antibacterial and antioxidant activity of thirty nine ho

118 berry and honeydew honeys showed the highest antibacterial and antioxidant activity.

119 r functional properties such as antioxidant, antibacterial and antitumoral activities.

120 This study investigated whether the potent antibacterial and antiviral functions of LL-37 were inhi

121 carbon black nanoparticles in vitro, and the antibacterial and antiviral functions of the peptide wer

122 nic infections for the chronopharmacology of antibacterial and antiviral therapies.

123 parated into three categories-antimicrobial, antibacterial and bacteriocins.

124 ory Bdellovibrio bacteriovorus are naturally antibacterial and combat infections by traversing, modif

125 teins with N-acetyl-d-glucosamine to inhibit antibacterial and inflammatory host responses.

126 atches in the ubiquitin coat, which serve as antibacterial and pro-inflammatory signalling platforms.

127 fication of common characteristics shared by antibacterial and self-assembling peptides provides a pa

128 difficulty of discovering new and effective antibacterials and the rapid development of resistance p

129 clinical and scientific use as an antiviral, antibacterial, and antitumor agent.

130 of diverse natural products with significant antibacterial, antifungal, antiviral, antiparasitic, ant

131 death (TLD), underlies the action of several antibacterial, antimalarial, anticancer, and immunomodul

132 shown several functional properties such as antibacterial, antiprotozoal, anti-inflammatory and anti

133 4) as a promising lead for development as an antibacterial/antitumor agent.

134 tors of the innate immune system with potent antibacterial, antiviral, and antifungal activity.

135 CRISPR-based antibacterials are a novel and adaptable method for buil

136 Our current antibacterial arsenal is composed of growth-inhibiting a

137 During antibacterial autophagy, ubiquitination of intracellular

138 To balance potential antibacterial benefit against risk of nephrotoxicity the

139 es resistance to one of the highly effective antibacterials, beta-lactams.

140 However, the intrinsic antibacterial capabilities of these assemblies have been

141 ability provide PTTP with a highly efficient antibacterial capability under a low light dose (0.6 J c

142 Triclosan (TCS) is a synthetic antibacterial chemical widely used in personal care prod

143 Drug resistance is a major problem in antibacterial chemotherapy.

144 tives to silver (Ag) nanoparticles (NPs) for antibacterial coatings.

145 cefepime-tazobactam (1:1; WCK 4282), a novel antibacterial combination consisting of the beta-lactama

146 ucine-rich repeat protein (PRELP) is a novel antibacterial component of innate immunity.

147 Copper (Cu) is a key antibacterial component of the host innate immune system

148 Given that defensin-1 and H2O2 are regular antibacterial components of all honeys, MW heating may h

149 ance gram-negative bacilli susceptibility to antibacterial components of the immune humoral arm.

150 a particular focus on two major bee-derived antibacterial components, defensin-1 and hydrogen peroxi

151 iosynthesis of the antitumor, antiviral, and antibacterial compound oxetanocin-A.

152 OXT-A) is a potent antitumour, antiviral and antibacterial compound.

153 For antibacterial compounds, generation of resistant mutants

154 on and, thus, allow the development of novel antibacterial compounds.

155 acterial enzymes are an important target for antibacterial compounds.

156 onventional GICs is inadequate for effectual antibacterial conservation in many cases.

157 ith a particular focus on the development of antibacterial cytotoxic T-cell responses.

158 acquisition at its single-cell stage and for antibacterial defense at its multicellular stages.

159 During pneumococcal pneumonia, antibacterial defense requires the orchestrated expressi

160 chniques may be detrimental to the epidermal antibacterial defense system by altering the microbiome.

161 ptimal innate immune cytokine production and antibacterial defense, demonstrating a novel role for RI

162 ned animals, including molecules involved in antibacterial defense, redox balance, and tissue healing

163 This defect was associated with suppressed antibacterial defenses, i.e., phagocyte recruitment, IgA

164 In order to improve antibacterial delivery, an anti-infective nanomaterial i

165 unexploited antibiotics as a source of novel antibacterial drug candidates.

166 sadvantages of different pull incentives for antibacterial drug development.

167 eas of consensus for economic incentives for antibacterial drug development.

168 from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif).

169 nt in ligase evolution and favors LigA as an antibacterial drug target.

170 Bacterial topoisomerases are attractive antibacterial drug targets because of their importance i

171 cterial SBPs are of considerable interest as antibacterial drug targets.

172 esses many of the requisite properties of an antibacterial drug, displaying potent and selective bact

173 include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unm

174 tivize companies to invest in developing new antibacterial drugs.

175 substantially reward the development of new antibacterial drugs.

176 This safe antibacterial dye induces cell death and apoptosis in se

177 employ the dropFAST platform to evaluate the antibacterial effect of gentamicin on E. coli growth.

178 ult to use because plasma concentrations for antibacterial effect overlap those causing nephrotoxicit

179 capacity (MIC); therefore presenting higher antibacterial effect.

180 ney (Leptospermum scoparium) exerts a strong antibacterial effect.

181 also proved to have antioxidant activity and antibacterial effects against Gram-positive bacteria, na

182 Results showed that antibacterial effects of the substrates could be maintai

183 e mechanisms by which pathogens resist Cam's antibacterial effects, and several different proteins ar

184 is modulatory property of hBD2, unrelated to antibacterial effects, gives new significance to the def

185 rately, but also exhibited their cooperative antibacterial effects.

186 ces may have an edge in creating a long-term antibacterial environment.

187 any efforts have been proposed to modify the antibacterial features of GICs in order to prevent the s

188 These webs show potential application as an antibacterial food packaging material.

189 report that deletion of the innate immunity antibacterial gene Nod2 abolishes this resistance, as No

190 velopments of GICs and challenges related to antibacterial GICs.

191 e the impact of peroral arsenic on pulmonary antibacterial host defense.

192 thetase 2, but does not affect expression of antibacterial human beta defensin 2 or regenerating isle

193 intestinal Salmonella infection by enhancing antibacterial IFNgamma responses.

194 erial surfaces into signalling platforms for antibacterial immunity reminiscent of antiviral assembli

195 ons of STING may have included activation of antibacterial immunity.

196 e efficiency of factor H (FH)6-7/Fc, a novel antibacterial immunotherapeutic protein against the Gram

197 emphasizing the potential of nitro drugs as antibacterials in various bacterial species.

198 A paucity of novel acting antibacterials is in development to treat the rising thr

199 ades, the repertoire of clinically effective antibacterials is shrinking due to the rapidly increasin

200 The mechanism of the beta-lactam antibacterials is the functionally irreversible acylatio

201 s were focused on the efficient discovery of antibacterial leads against 119 targets from Acinetobact

202 d ROS, associated with LC3, and matured into antibacterial lysosomes.

203 showcased by the construction of the potent antibacterial marine natural product bromophycoic acid E

204 membrane interactions and the development of antibacterial materials by integration of the peptide as

205 The apidaecins have special antibacterial mechanisms, and are non-toxic for human ce

206 This novel antibacterial mode of action holds a low risk to induce

207 tically the extant researches addressing the antibacterial modifications in GICs in order to provide

208 We hypothesize that the heightened antibacterial monocyte responses after vaccination of TO

209 ownstream signaling regulated the release of antibacterial myeloperoxidase and lactoferrin.

210 In detail, our strategy combines antibacterial nanotopographical features with integrin s

211 plied to the synthesis of the broad spectrum antibacterial natural product (-)-4-(1,5-dimethylhex-4-e

212 The cystobactamids are a family of antibacterial natural products with unprecedented chemic

213 ture provided some mechanistic insights into antibacterial peptide efflux.

214 The ABC transporter McjD exports the antibacterial peptide MccJ25 in Escherichia coli Our pre

215 First, a library of antibacterial peptides is screened that combines a membr

216 photo-activated contributions to the overall antibacterial performance of the surfaces, demonstrating

217 The antibacterial polyketide compounds described in the pres

218 ed, Laurenciae papillosa was used to isolate antibacterial polyketide compounds.

219 milarities but have a ten-fold difference in antibacterial potency towards Gram-negative bacteria.

220 adaptable method for building an arsenal of antibacterials potentially capable of targeting any path

221 Surprisingly, for antibacterial prediction, the original AntiBP method sig

222 onochemical method via in situ deposition of antibacterial prickly Zn-CuO nanoparticles and graphene

223 land, and has been widely recognised for its antibacterial properties and specific taste.

224 thiostrepton, a complex molecule with potent antibacterial properties for which few analogues are kno

225 nt types of skeletons and substitutions, and antibacterial properties of extracts was investigated.

226 In this work, we reported the antibacterial properties of micrometer-thick titanium ca

227 e significantly (p<0.01) correlated with the antibacterial properties of the extracts.

228 re based on diaminopyrimidines with suitable antibacterial properties was identified.

229 al products used for alleged therapeutic and antibacterial properties.

230 es of linear guanidine derivatives and their antibacterial properties.

231 This is the largest study to date of antibacterial prophylaxis during induction therapy for p

232 d a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT.

233 Although routine in adults with leukemia, antibacterial prophylaxis is controversial in pediatrics

234 to sensitize gram-negative bacilli to innate antibacterial protagonists.

235 h a human pathogen appropriates an arthropod antibacterial protein to alter the gut microbiota and mo

236 sensitization to endogenous and/or exogenous antibacterial proteins such as lysozyme and complements.

237 Axinellamines A and B are broad-spectrum antibacterial pyrrole-imidazole alkaloids that have a co

238 a low concentration of 50 CFU mL(-1), rapid antibacterial rate (100% killing in 30min) and high dete

239 The antibacterial rate of fresh Ti3C2Tx MXene membranes reac

240 me time in-depth understanding of controlled antibacterial release in this class of biomaterials.

241 r the past several decades, the frequency of antibacterial resistance in hospitals, including multidr

242 Antibacterial resistance is increasing globally and has

243 This article describes the activities of the Antibacterial Resistance Leadership Group (ARLG) in the

244 ission of the Gram-Positive Committee of the Antibacterial Resistance Leadership Group (ARLG) is to a

245 The Antibacterial Resistance Leadership Group (ARLG) Laborat

246 litating, coordinating, and implementing the Antibacterial Resistance Leadership Group (ARLG) scienti

247 d Data Management Center (SDMC) provides the Antibacterial Resistance Leadership Group (ARLG) with st

248 The Antibacterial Resistance Leadership Group (ARLG), with f

249 reas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG).

250 Therefore, the Antibacterial Resistance Leadership Group has identified

251 The Antibacterial Resistance Leadership Group proposes a str

252 t systematic analysis of research funding of antibacterial resistance of this scale and scope, which

253 n order to retard the rate of development of antibacterial resistance, the causative agent must be id

254 t is needed to address the current crisis of antibacterial resistance.

255 s to address the ever-changing priorities in antibacterial resistance.

256 e inhibitors, important as a defence against antibacterial resistance.

257 a that addresses the public health threat of antibacterial resistance.

258 ew therapeutic opportunities to modulate the antibacterial response and improve clinical outcome.

259 he host phosphatase PPM1A, which impairs the antibacterial response of macrophages.

260 can, the component that activates Drosophila antibacterial response, is also the elicitor of this beh

261 ible NO synthase-producing DCs dominated the antibacterial response.

262 can interactions may contribute to reinforce antibacterial responses by reprogramming innate and adap

263 tica pathogenicity by undermining protective antibacterial responses.

264 Our study uncovers a unique antibacterial role for HMOs against a leading neonatal p

265 our research efforts aimed at expanding the antibacterial spectrum of this class of molecules toward

266 ibition of RECON promotes a proinflammatory, antibacterial state that is distinct from the antiviral

267 a manner independent of STING to promote an antibacterial state.

268 Antibacterial stewardship is the coordinated effort to i

269 tance Leadership Group (ARLG) in the area of antibacterial stewardship.

270 ercome this barrier can point the way to new antibacterial strategies (1) , especially small lytic si

271 ells an enhanced ability to tolerate diverse antibacterial stresses.

272 nine, which emerges as the minimal model for antibacterial supramolecular polymers.

273 Photo-responsive antibacterial surfaces combining both on-demand photo-sw

274 A simple procedure to develop antibacterial surfaces using thiol-capped gold nanoparti

275 The detection of antibacterial susceptibility response by a capacitive sy

276 A simple renewable surface for a rapid antibacterial susceptibility test has been demonstrated.

277 Antibacterial susceptibility testing shows minimum inhib

278 ng, synthetic chemistry, enzyme kinetics and antibacterial susceptibility testing.

279 e established effector-immunity paradigm for antibacterial T6SS substrates, the toxic activities of t

280 ry feedback that has elicited interest as an antibacterial target.

281 Here, we report that GA is antibacterial, targeting Gram-negative organisms with hi

282 Antibacterials that disrupt cell membrane function have

283 e increases sensitivity to fluoroquinolones; antibacterials that kill cells by inhibiting topoisomera

284 Fluoroquinolones are broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA

285 ave exceptional potential as targets for new antibacterial therapeutic agents.

286 his enzymatic activity as a potential future antibacterial therapeutic approach.

287 ing interest in nontraditional approaches to antibacterial therapies.

288 this pathway as a target for development of antibacterial therapies.

289 useful strategy to design new approaches to antibacterial therapy.

290 PUM is a highly promising lead for antibacterial therapy.

291 ve protein was 71% for both biomarkers after antibacterial therapy.

292 es stabilize double-stranded DNA breaks, the antibacterial thiophenes stabilize gyrase-mediated DNA-c

293 We have identified a class of antibacterial thiophenes that target DNA gyrase with a u

294 Antibacterial toxins of the colicin family, which could

295 trials to assess the feasibility of reducing antibacterial usage while preserving patient outcome.

296 g pandemic infectious threats, inappropriate antibacterial use contributing to multidrug resistance,

297 Robust antibacterial vaccines have prevented and reduced resist

298 acycline and ampicillin, two clinically used antibacterials, was observed.

299 ged approach investigating the metabolism of antibacterials within both the host and bacterium is out

300 chniques to study the fate of small-molecule antibacterials within the targeted organism.